Acute Respiratory Distress Syndrome (ARDS) - Market Insight, Epidemiology And Market Forecast - 2032

Table of Content

1. Key Insights

2. Report Introduction

3. Acute Respiratory Distress Syndrome Market Overview at a Glance
3.1. Market Share (%) Distribution of Acute Respiratory Distress Syndrome by Therapies in 2019
3.2. Market Share (%) Distribution of Acute Respiratory Distress Syndrome by Therapies in 2032

4. Acute Respiratory Distress Syndrome Market: Future Perspective

5. Executive Summary of Acute Respiratory Distress Syndrome

6. Key Events

7. Disease Background and Overview
7.1. Introduction of Acute Respiratory Distress Syndrome
7.1.1. Consensus Definitions of Acute Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
7.1.2. Development of Berlin Definition of ARDS
7.1.3. Problems with the AECC definition and subsequent Berlin definition of ARDS
7.2. Causes and Risk Factors
7.2.1. Risk Factors of Acute Respiratory Distress Syndrome
7.2.1.1. ARDS associated with Covid-19
7.3. Pathophysiology of Acute Respiratory Distress Syndrome
7.4. Stages of Acute Respiratory Distress Syndrome
7.5. Ventilator-Induced Lung Injury (VILI)
7.6. Diagnosis of Acute Respiratory Distress Syndrome
7.6.1. Differential Diagnosis
7.7. Treatment and Management of Acute Respiratory Distress Syndrome
7.7.1. Treatment of ALI/ARDS associated with Covid-19
7.8. Treatment Guidelines
7.8.1. American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome
7.8.2. Clinical Practice Guideline by the Japanese Society of Respiratory Care Medicine and the Japanese Society of Intensive Care Medicine for the management of ARDS in Japan
7.8.3. Infectious Diseases Society of America (IDSA) Guidelines on the Treatment and Management of Patients with Covid-19
7.8.4. WHO guidance for the treatment of ARDS associated with Covid-19

8. Epidemiology and Patient Population
8.1. Key Findings
8.2. Methodology of Epidemiology
8.3. Assumptions and Rationale: 7MM
8.3.1. The United States
8.3.2. The Five European Countries (Germany, France, Italy, Spain, and the United Kingdom)
8.3.3. Japan
8.4. Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM
8.5. The United States
8.5.1. Total Incident Cases of Acute Respiratory Distress Syndrome in the United States
8.5.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in the United States
8.5.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the United States
8.6. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)
8.6.1. Germany
8.6.1.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Germany
8.6.1.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Germany
8.6.1.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Germany
8.6.2. France
8.6.2.1. Total Incident Cases of Acute Respiratory Distress Syndrome in France
8.6.2.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in France
8.6.2.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in France
8.6.3. Italy
8.6.3.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Italy
8.6.3.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Italy
8.6.3.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Italy
8.6.4. Spain
8.6.4.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Spain
8.6.4.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Spain
8.6.4.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Spain
8.6.5. The United Kingdom
8.6.5.1. Total Incident Cases of Acute Respiratory Distress Syndrome in the UK
8.6.5.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in the UK
8.6.5.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the UK
8.7. Japan
8.7.1. Total Incident Cases of Acute Respiratory Distress Syndrome in Japan
8.7.2. Severity-specific Cases of Acute Respiratory Distress Syndrome in Japan
8.7.3. Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Japan

9. Patient Journey

10. Off-Label Therapies for ARDS
10.1. Neuromuscular Blocking Agents (NMBAs)
10.1.1. Product Description
10.1.1.1. Evidence of NMBA use in ARDS
10.1.2. Mechanism of Action
10.1.3. Advantages and Disadvantages
10.1.4. Clinical Development
10.2. Inhaled Vasodilators
10.2.1. Product Description
10.2.2. Inhaled Pulmonary Vasodilators
10.2.2.1. Evidence of IV use in ARDS
10.2.2.2. Inhaled Nitric Oxide
10.2.2.3. Inhaled Prostacyclins
10.2.3. Advantages and Disadvantages
10.2.4. Clinical Development
10.3. Corticosteroids
10.3.1. Product Description
10.3.2. Mechanism of Action
10.3.3. Advantages and Disadvantages
10.3.4. Clinical Development

11. Emerging Drugs
11.1. Key Competitors
11.2. EB05: Edesa Biotech
11.2.1. Product Description
11.2.2. Clinical Development
11.2.2.1. Clinical Trials Information
11.2.3. Safety and Efficacy
11.2.4. Product Profile
11.2.5. Analysts’ Views
11.3. Alteplase (Actilyse): Boehringer Ingelheim/ Genentech
11.3.1. Product Description
11.3.2. Other Developmental Activities
11.3.3. Clinical Development
11.3.3.1. Clinical Trials Information
11.3.4. Product Profile
11.3.5. Analysts’ Views
11.4. Lucinactant (Sinapultide (KL4) Surfactant): Windtree Therapeutics
11.4.1. Product Description
11.4.2. Other Developmental Activities
11.4.3. Clinical Development
11.4.3.1. Clinical Trials Information
11.4.4. Safety and Efficacy
11.4.5. Product Profile
11.4.6. Analysts’ Views
11.5. BIO-11006: BioMarck Pharmaceuticals
11.5.1. Product Description
11.5.2. Other Development Activities
11.5.3. Clinical Development
11.5.3.1. Clinical Trials Information
11.5.4. Safety and Efficacy
11.5.5. Product Profile
11.5.6. Analysts’ Views
11.6. MultiStem (HLCM051): Athersys
11.6.1. Product Description
11.6.2. Other Development Activities
11.6.3. Clinical Development
11.6.3.1. Clinical Trials Information
11.6.4. Safety and Efficacy
11.6.5. Product Profile
11.6.6. Analysts’ Views
11.7. RLF-100 (Zyesami/Aviptadil): NeuroRx/Relief Therapeutics
11.7.1. Product Description
11.7.2. Other Development Activities
11.7.3. Clinical Development
11.7.3.1. Clinical Trials Information
11.7.4. Safety and Efficacy
11.7.5. Product Profile
11.7.6. Analysts’ Views
11.8. ExoFlo (DB-001): Direct Biologics
11.8.1. Product Description
11.8.2. Other Development Activities
11.8.3. Clinical Development
11.8.3.1. Clinical Trials Information
11.8.4. Safety and Efficacy
11.8.5. Product Profile
11.8.6. Analysts’ Views
11.9. Traumakine: Faron Pharmaceuticals
11.9.1. Product Description
11.9.2. Other Development Activities
11.9.3. Clinical Development
11.9.3.1. Clinical Trials Information
11.9.4. Safety and Efficacy
11.9.5. Product Profile
11.10. Solnatide (AP301): APEPTICO Forschung und Entwicklung GmbH
11.10.1. Product Description
11.10.2. Other Development Activities
11.10.3. Clinical Development
11.10.3.1. Clinical Trials Information
11.10.4. Safety and Efficacy
11.10.5. Product Profile
11.11. Cholecalciferol: Mylan Laboratories
11.11.1. Product Description
11.11.2. Clinical Development
11.11.2.1. Clinical Trials Information
11.11.3. Product Profile
11.12. BDB-001: Staidson (Beijing) Biopharmaceuticals
11.12.1. Product Description
11.12.2. Other Development Activities
11.12.3. Clinical Development
11.12.3.1. Clinical Trials Information
11.12.4. Product Profile
11.13. Zavegepant/Vazegepant: Biohaven Pharmaceutical
11.13.1. Product Description
11.13.2. Other Development Activities
11.13.3. Clinical Development
11.13.3.1. Clinical Trials Information
11.13.4. Product Description
11.14. Metablok (LSALT peptide): Arch Biopartners
11.14.1. Product Description
11.14.2. Other Development Activities
11.14.3. Clinical Development
11.14.3.1. Clinical Trials Information
11.14.4. Safety and Efficacy
11.14.5. Product Profile
11.15. Lenzilumab: Humanigen
11.15.1. Product Description
11.15.2. Other Development Activities
11.15.3. Clinical Development
11.15.3.1. Clinical Trials Information
11.15.4. Safety and Efficacy
11.15.5. Product Profile
11.16. Veru-111: Veru
11.16.1. Product Description
11.16.2. Clinical Development
11.16.2.1. Clinical Trial Information
11.16.3. Safety and Efficacy
11.16.4. Product Profile
11.17. Human immunoglobulin: Laboratoire fran?ais de Fractionnement et de Biotechnologies (LFB)
11.17.1. Product Description
11.17.2. Clinical Development
11.17.3. Product Profile
11.18. Remestemcel-L: Mesoblast Limited
11.18.1. Product Description
11.18.2. Other Development Activities
11.18.3. Clinical Development
11.18.3.1. Clinical Trial Information
11.18.4. Product Profile
11.19. PLX-PAD: Pluristem Therapeutics
11.19.1. Product Description
11.19.2. Other Development Activities
11.19.3. Clinical Development
11.19.3.1. Clinical Trials Information
11.19.4. Safety and Efficacy
11.19.5. Product Profile
11.20. CERC-002: Cerecor
11.20.1. Product Description
11.20.2. Other Development Activities
11.20.3. Clinical Development
11.20.3.1. Clinical Trials Information
11.20.4. Safety and Efficacy
11.20.5. Product Profile
11.21. TD-0903: Theravance Biopharma
11.21.1. Product Description
11.21.2. Clinical Development
11.21.2.1. Clinical Trials Information
11.21.3. Product Profile
11.22. ILT101: ILTOO Pharma
11.22.1. Product Description
11.22.2. Clinical Development
11.22.2.1. Clinical Trials Information
11.22.3. Product Profile

12. Acute Respiratory Distress Syndrome: Seven Major Market Analysis
12.1. Key Findings
12.2. Methodology of Acute Respiratory Distress Syndrome Market
12.3. Market Outlook
12.4. Key Market Forecast Assumptions
12.5. Attribute Analysis
12.6. Market Size of Acute Respiratory Distress Syndrome in the 7MM
12.7. Market Size of Acute Respiratory Distress Syndrome by Therapies in the 7MM
12.8. Market Size of Acute Respiratory Distress Syndrome in the United States
12.8.1. Total Market Size of Acute Respiratory Distress Syndrome
12.8.2. Market Size of Acute Respiratory Distress Syndrome by Therapies
12.9. Market Size of Acute Respiratory Distress Syndrome in the EU-5
12.9.1. Germany
12.9.1.1. Total Market Size of Acute Respiratory Distress Syndrome
12.9.1.2. Market Size of Acute Respiratory Distress Syndrome by Therapies
12.9.2. France
12.9.2.1. Total Market Size of Acute Respiratory Distress Syndrome
12.9.2.2. Market Size of Acute Respiratory Distress Syndrome by Therapies
12.9.3. Italy
12.9.3.1. Total Market Size of Acute Respiratory Distress Syndrome
12.9.3.2. Market Size of Acute Respiratory Distress Syndrome by Therapies
12.9.4. Spain
12.9.4.1. Total Market Size of Acute Respiratory Distress Syndrome
12.9.4.2. Market Size of Acute Respiratory Distress Syndrome by Therapies
12.9.5. The United Kingdom
12.9.5.1. Total Market Size of Acute Respiratory Distress Syndrome
12.9.5.2. Market Size of Acute Respiratory Distress Syndrome by Therapies
12.10. Market Size of Acute Respiratory Distress Syndrome in Japan
12.10.1. Total Market Size of Acute Respiratory Distress Syndrome
12.10.2. Market Size of Acute Respiratory Distress Syndrome by Therapies

13. Key Opinion Leaders’ Views

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Reimbursement and Market Access

18. Unmet Needs

19. Appendix
19.1. Bibliography
19.2. Report Methodology

20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

List of Figures

Figure 1: Risk factors of Acute Respiratory Distress Syndrome
Figure 2: A simplified model of the pathogenesis of Acute Respiratory Distress syndrome
Figure 3: Effects of Mast Cell Activation
Figure 4: Treatment Algorithm for ARDS
Figure 5: Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM (2019–2032)
Figure 6: Incident Cases of Acute Respiratory Distress Syndrome in the US (2019–2032)
Figure 7: Severity-specific Cases of Acute Respiratory Distress Syndrome in the US (2019–2032)
Figure 8: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the US (2019–2032)
Figure 9: Total Incident Cases of Acute Respiratory Distress Syndrome in Germany (2019–2032)
Figure 10: Severity-specific Cases of Acute Respiratory Distress Syndrome in Germany (2019–2032)
Figure 11: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Germany (2019–2032)
Figure 12: Total Incident Cases of Acute Respiratory Distress Syndrome in France (2019–2032)
Figure 13: Severity-specific Cases of Acute Respiratory Distress Syndrome in France (2019–2032)
Figure 14: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in France (2019–2032)
Figure 15: Total Incident Cases of Acute Respiratory Distress Syndrome in Italy (2019–2032)
Figure 16: Severity-specific Cases of Acute Respiratory Distress Syndrome in Italy (2019–2032)
Figure 17: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Italy (2019–2032)
Figure 18: Total Incident Cases of Acute Respiratory Distress Syndrome in Spain (2019–2032)
Figure 19: Severity-specific Cases of Acute Respiratory Distress Syndrome in Spain (2019–2032)
Figure 20: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Spain (2019–2032)
Figure 21: Total Incident Cases of Acute Respiratory Distress Syndrome in the UK (2019–2032)
Figure 22: Severity-specific Cases of Acute Respiratory Distress Syndrome in the UK (2019–2032)
Figure 23: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the UK (2019–2032)
Figure 24: Total Incident Cases of Acute Respiratory Distress Syndrome in Japan (2019–2032)
Figure 25: Severity-specific Cases of Acute Respiratory Distress Syndrome in Japan (2019–2032)
Figure 26: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Japan (2019–2032)
Figure 27: Patient Journey
Figure 28: Market Size of Acute Respiratory Distress Syndrome in the 7MM, USD Millions (2019–2032)
Figure 29: Market Size of Acute Respiratory Distress Syndrome by Therapies in the 7MM, in USD Million (2019–2032)
Figure 30: Market Size of Acute Respiratory Distress Syndrome in the United States, USD Millions (2019–2032)
Figure 31: Market Size of Acute Respiratory Distress Syndrome by Therapies in the United States, in USD Million (2019–2032)
Figure 32: Total Market Size of Acute Respiratory Distress Syndrome in Germany, USD Millions (2019–2032)
Figure 33: Market Size of Acute Respiratory Distress Syndrome by Therapies in Germany, in USD Million (2019–2032)
Figure 34: Total Market Size of Acute Respiratory Distress Syndrome in France, USD Millions (2019–2032)
Figure 35: Market Size of Acute Respiratory Distress Syndrome by Therapies in France, in USD Million (2019–2032)
Figure 36: Total Market Size of Acute Respiratory Distress Syndrome in Italy, USD Millions (2019–2032)
Figure 37: Market Size of Acute Respiratory Distress Syndrome by Therapies in Italy, in USD Million (2019–2032)
Figure 38: Total Market Size of Acute Respiratory Distress Syndrome in Spain, USD Millions (2019–2032)
Figure 39: Market Size of Acute Respiratory Distress Syndrome by Therapies in Spain, in USD Million (2019–2032)
Figure 40: Total Market Size of Acute Respiratory Distress Syndrome in the UK, USD Millions (2019–2032)
Figure 41: Market Size of Acute Respiratory Distress Syndrome by Therapies in the UK, in USD Million (2019–2032)
Figure 42: Market Size of Acute Respiratory Distress Syndrome in Japan, USD Millions (2019–2032)
Figure 43: Market Size of Acute Respiratory Distress Syndrome by Therapies in Japan, in USD Million (2019–2032)
Figure 44: Market Drivers
Figure 45: Market Barriers
Figure 46: SWOT Analysis
Figure 47: Unmet Needs

List of Tables

Table 1: Summary of Acute Respiratory Distress Syndrome Market and Epidemiology (2019–2032)
Table 2: Key Events
Table 3: Definition of Acute Respiratory Distress Syndrome
Table 4: American European Consensus Conference Criteria for Acute Lung Injury (ALI) and the Acute Respiratory Distress Syndrome (ARDS)
Table 5: Berlin Definition of Mild, Moderate, and Severe Acute Respiratory Distress Syndrome (ARDS)
Table 6: Factors That Distinguish ARDS, CHF, and Pneumonia
Table 7: Management of Acute Respiratory Distress Syndrome (ARDS)
Table 8: Spontaneous Breathing Trial
Table 9: Therapeutic options for severe acute respiratory distress syndrome related to coronavirus disease 2019
Table 10: Recommendations for Specific Treatment Questions for the Management of ARDS
Table 11: The Clinical Practice Guideline for The Management of ARDS in Japan
Table 12: Recommendations by the Infectious Diseases Society of America
Table 13: Total Incident Population of Acute Respiratory Distress Syndrome in the 7MM (2019–2032)
Table 14: Total Incident Cases of Acute Respiratory Distress Syndrome in the US (2019–2032)
Table 15: Severity-specific Cases of Acute Respiratory Distress Syndrome in the US (2019–2032)
Table 16: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the US (2019–2032)
Table 17: Total Incident Cases of Acute Respiratory Distress Syndrome in Germany (2019–2032)
Table 18: Severity-specific Cases of Acute Respiratory Distress Syndrome in Germany (2019–2032)
Table 19: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Germany (2019–2032)
Table 20: Total Incident Cases of Acute Respiratory Distress Syndrome in France (2019–2032)
Table 21: Severity-specific Cases of Acute Respiratory Distress Syndrome in France (2019–2032)
Table 22: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in France (2019–2032)
Table 23: Total Incident Cases of Acute Respiratory Distress Syndrome in Italy (2019–2032)
Table 24: Severity-specific Cases of Acute Respiratory Distress Syndrome in Italy (2019–2032)
Table 25: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Italy (2019–2032)
Table 26: Total Incident Cases of Acute Respiratory Distress Syndrome in Spain (2019–2032)
Table 27: Severity-specific Cases of Acute Respiratory Distress Syndrome in Spain (2019–2032)
Table 28: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Spain (2019–2032)
Table 29: Total Incident Cases of Acute Respiratory Distress Syndrome in the UK (2019–2032)
Table 30: Severity-specific Cases of Acute Respiratory Distress Syndrome in the UK (2019–2032)
Table 31: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in the UK (2019–2032)
Table 32: Total Incident Cases of Acute Respiratory Distress Syndrome in Japan (2019–2032)
Table 33: Severity-specific Cases of Acute Respiratory Distress Syndrome in Japan (2019–2032)
Table 34: Incident Cases of Acute Respiratory Distress Syndrome by Risk Factors in Japan (2019–2032)
Table 35: Comparison of Emerging Drugs Under Development
Table 36: EB05, Clinical Trial Description, 2022
Table 37: Alteplase, Clinical Trial Description, 2022
Table 38: Lucinactant, Clinical Trial Description, 2022
Table 39: BIO-11006, Clinical Trial Description, 2022
Table 40: MultiStem, Clinical Trial Description, 2022
Table 41: RLF-100 (aviptadil), Clinical Trial Description, 2022
Table 42: ExoFlo (DB-001), Clinical Trial Description, 2022
Table 43: Traumakine, Clinical Trial Description, 2022
Table 44: Solnatide (AP301), Clinical Trial Description, 2022
Table 45: Cholecalciferol, Clinical Trial Description, 2022
Table 46: BDB-001, Clinical Trial Description, 2022
Table 47: Vazegepant, Clinical Trial Description, 2022
Table 48: LSALT peptide, Clinical Trial Description, 2022
Table 49: Lenzilumab, Clinical Trial Description, 2022
Table 50: VERU-111, Clinical Trial Description, 2022
Table 51: Remestemcel-L, Clinical Trial Description, 2022
Table 52: PLX-PAD Clinical Trial Description, 2022
Table 53: CERC-002, Clinical Trial Description, 2022
Table 54: TD-0903, Clinical Trial Description, 2022
Table 55: ILT-101, Clinical Trial Description, 2022
Table 56: Key Market Forecast Assumptions for EB05
Table 57: Key Market Forecast Assumptions for BIO-11006
Table 58: Key Market Forecast Assumptions for MultiStem
Table 59: Key Market Forecast Assumptions for Alteplase
Table 60: Key Market Forecast Assumptions for Lucinactant
Table 61: Key Market Forecast Assumptions for DB-001
Table 62: Key Market Forecast Assumptions for Aviptadil
Table 63: Market Size of Acute Respiratory Distress Syndrome in the 7MM, USD Millions (2019–2032)
Table 64: Market Size of Acute Respiratory Distress Syndrome by Therapies in the 7MM, in USD Million (2019–2032)
Table 65: Market Size of Acute Respiratory Distress Syndrome in the United States, USD Millions (2019–2032)
Table 66: Market Size of Acute Respiratory Distress Syndrome by Therapies in the United States, in USD Million (2019–2032)
Table 67: Total Market Size of Acute Respiratory Distress Syndrome in Germany, USD Millions (2019–2032)
Table 68: Market Size of Acute Respiratory Distress Syndrome by Therapies in Germany, in USD Million (2019–2032)
Table 69: Total Market Size of Acute Respiratory Distress Syndrome in France, USD Millions (2019–2032)
Table 70: Market Size of Acute Respiratory Distress Syndrome by Therapies in France, in USD Million (2019–2032)
Table 71: Total Market Size of Acute Respiratory Distress Syndrome in Italy, USD Millions (2019–2032)
Table 72: Market Size of Acute Respiratory Distress Syndrome by Therapies in Italy, in USD Million (2019–2032)
Table 73: Total Market Size of Acute Respiratory Distress Syndrome in Spain, USD Millions (2019–2032)
Table 74: Market Size of Acute Respiratory Distress Syndrome by Therapies in Spain, in USD Million (2019–2032)
Table 75: Total Market Size of Acute Respiratory Distress Syndrome in the UK, USD Millions (2019–2032)
Table 76: Market Size of Acute Respiratory Distress Syndrome by Therapies in the UK, in USD Million (2019–2032)
Table 77: Market Size of Acute Respiratory Distress Syndrome in Japan, USD Millions (2019–2032)
Table 78: Market Size of Acute Respiratory Distress Syndrome by Therapies in Japan, in USD Million (2019–2032)